KRAS and familial pancreatic carcinoma: The ability to characterise CTCs downstream of ISET filtration in a flexible manner may facilitate measurement of predictive biomarkers allowing stratification of pancreatic cancer patients most likely to benefit from novel targeted therapies, for example, KRAS and EGFR mutation analysis.